• Clive Brown on Field Biopsies, New Chemistry, Short Reads

    Dec 03 | Bio-IT World | At Oxford Nanopore’s virtual Community Meeting this week, CTO Clive Brown presented new chemistries, previewed the Apple iPad Pro-powered Mk1D with an integrated MinION, teased the diagnostic capacities of “outy” sequencing, unveiled a browser base caller, and more. More
  • Follow the Money: Cloud R&D, Generative Biology, Robotics

    Dec 02 | Bio-IT World | Platforms for machine-learning generative biology and cloud R&D, drug delivery chip for therapies at the tumor site, and AI-driven drug discovery and robotics. More
  • Cloud Hygiene and Cost Optimization at Johnson & Johnson

    Dec 01 | Bio-IT World | TRENDS FROM THE TRENCHES—Tom Messina has worked in various roles for Johnson & Johnson dating back to 1999 and is currently an IT Director in J&J’s Pharmaceutical R&D division, Janssen. BioTeam had a chance to speak with Tom recently to appreciate how J&J is leveraging cloud compute and storage resources to maximize innovation and growth while controlling costs. More
  • Gilead Chooses AWS, Illumina, Sequoia Fund Chinese Startups, More

    Nov 30 | Bio-IT World | Illumina powers the Canadian COVID-19 Genomics Network, organ-on-a-chip explores infectious disease, and cell analysis acquisitions. Plus new products from PerkinElmer, Bio-Rad, Roswell Biotechnologies, Genialis, and more. More
  • Building the Data Foundation for Faster Time to Science in Healthcare

    Nov 23 | Bio-IT World | Genomics and artificial intelligence (AI) are key to this quest and at-scale advancement of personalized medicine. Both, however, require liquid data and modern data infrastructure that re-imagines the role of data and how it is used. More
  • Gut Microbiome Linked To Aggressive Prostate Cancer

    Nov 22 | Bio-IT World | Evidence has been mounting for decades that what men eat can lower or raise their risk of prostate cancer—including aggressive forms of the disease that can be lethal. But that’s only part of the story. More
  • Biopharma’s Dark Data Problem

    Nov 19 | Bio-IT World | Worldwide spending on pharmaceutical R&D will reach $230 billion by 2026. So with investment dollars flowing in and R&D continuing an upward trajectory all should be well, right? Well… not exactly. Like many industries, pharmaceutical companies are facing a data problem—a dark data problem. More
  • Recursion’s Vision for the New Shape of Drug Discovery

    Nov 17 | Bio-IT World | As a “digital native,” Recursion is working to reshape the drug discovery industry—quite literally. Gone is the vision of a traditional discovery funnel, wide at the top and slowly narrowing. Instead, Recursion proposes a drug discovery machine powering a T-shaped funnel where many options are considered, but failure is fast and the candidates that advance have a potentially higher likelihood of being a successful treatment. Easier said than done. More
View more articles
Bio IT World Lead Gen


Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!


Digital Therapeutics: Taking digital health to a new level
Benchling is the most widely-adopted life sciences R&D cloud. Accelerate, measure, and forecast R&D – from discovery through bioprocessing – all in one place. It’s a fully unified platform that centralizes and standardizes all R&D data, so you can spend less time fighting with legacy software, and more time reaching breakthrough discoveries.
Read more here!